HOUSE_OVERSIGHT_028417.jpg
3.31 MB
Extraction Summary
2
People
5
Organizations
2
Locations
5
Events
3
Relationships
4
Quotes
Document Information
Type:
Data extract from a news article, identified as exhibit 'house oversight 028417'.
File Size:
3.31 MB
Summary
This document is a data extract, likely from a news article, which has been marked as an exhibit for a House Oversight investigation. The text details the history of the pharmaceutical company Celgene and its drug Thalomid (thalidomide), including its approval by the F.D.A. in 1998 and the context of executive Bob Hugin's subsequent political career. The document contains no information related to Jeffrey Epstein or his associates.
People (2)
| Name | Role | Context |
|---|---|---|
| Mr. Hugin | Executive at Celgene, Political Candidate |
Mentioned as arriving at Celgene in June 1999. Also mentioned as a political candidate in New Jersey facing difficult...
|
| Mr. Menendez | Political Candidate |
Mentioned as a political opponent of Mr. Hugin in a New Jersey race. Noted to have vulnerabilities, but benefits from...
|
Organizations (5)
| Name | Type | Context |
|---|---|---|
| Celgene |
A pharmaceutical company in New Jersey that marketed the drug Thalomid (thalidomide). Mr. Hugin arrived there in June...
|
|
| F.D.A. (Food and Drug Administration) |
The U.S. regulatory body that approved Celgene's application for thalidomide in 1998 and mandated a strict distributi...
|
|
| Democrats |
Political party mentioned as having nearly 900,000 more registered voters than Republicans in New Jersey.
|
|
| Republicans |
Political party mentioned in the context of New Jersey voter registration numbers.
|
|
| HOUSE_OVERSIGHT |
Appears in the footer of the document ('HOUSE_OVERSIGHT_028417'), suggesting this document is an exhibit for a congre...
|
Timeline (5 events)
1960s
The drug thalidomide became notorious after being traced to thousands of birth defects worldwide.
Worldwide
1990s
Thalidomide, previously obscure, saw a resurgence in interest. AIDS activists were smuggling it into the U.S. and selling it via 'buyers clubs' for AIDS-related conditions.
United States
AIDS activists
Locations (2)
| Location | Context |
|---|---|
|
The location of Celgene and the political race between Mr. Hugin and Mr. Menendez.
|
|
|
Location where leprosy is extremely rare and where the F.D.A. regulates drugs.
|
Relationships (3)
Text states 'When Mr. Hugin arrived at Celgene in June 1999...'
Text describes a political race in New Jersey between the two.
Text describes Celgene getting drug approval from the F.D.A. and being required to follow its distribution rules.
Key Quotes (4)
"When Mr. Hugin arrived at Celgene in June 1999, the company was struggling to figure out how to turn a profit on its only marketed drug, Thalomid, which had been approved a year earlier to treat a rare skin condition caused by leprosy."Source
HOUSE_OVERSIGHT_028417.jpg
Quote #1
"Thalomid was Celgene’s brand name for thalidomide, an old drug that became notorious in the 1960s after it was traced to thousands of birth defects worldwide."Source
HOUSE_OVERSIGHT_028417.jpg
Quote #2
"F.D.A. officials, alarmed that a notorious drug was being sold illicitly, took the unusual step of seeking out drug companies that might be willing to bring thalidomide to market legally."Source
HOUSE_OVERSIGHT_028417.jpg
Quote #3
"But leprosy was hardly the point: The F.D.A.’s main goal was to keep the drug from harming infants, and it did so by requiring that Celgene set up a first-of-its-kind distribution system that would limit prescriptions to preapproved doctors and pharmacies."Source
HOUSE_OVERSIGHT_028417.jpg
Quote #4
Full Extracted Text
Complete text extracted from the document (5,161 characters)
1"},{"range":{"length":277,"start":0},"textstyle":" anf-ts-1"}],"layout": "default-
body", "role":"body","text":"Any broad swing in voter opinion could prove difficult for
Mr. Hugin to overcome. Even with Mr. Menendez’s vulnerabilities, New Jersey has
nearly 900,000 more registered Democrats than Republicans, and a number of competitive
House races that have attracted national
attention.","type":"text"}, {"bannerType":"any","identifier":"anf-banner_advertisement-
3","layout":"ComponentLayout-
4","role":"banner_advertisement","type":"banner_advertisement"},{"identifier":"anf-
heading4-1","layout":"heading4","role":"heading4","text": "A once-notorious drug becomes
a lucrative cancer weapon", "type":"text"},{"identifier":"
anf-body-
19","inlineTextStyles":[{"range":{"length":235,"start":0},"textStyle":"_anf-ts-
1"},{"range":{"length":235,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-
body", "role":"body","text":"When Mr. Hugin arrived at Celgene in June 1999, the company
was struggling to figure out how to turn a profit on its only marketed drug, Thalomid,
which had been approved a year earlier to treat a rare skin condition caused by
leprosy.","type":"text"},{"identifier":" anf-body-
20","inlineTextStyles":[{"range":{"length":158,"start":0},"textStyle":" anf-ts-
1"},{"range":{"length":158,"start":0},"textstyle":"anf-ts-1"}],"layout":"default-
body", "role":"body","text":"Thalomid was Celgene’s brand name for thalidomide, an old
drug that became notorious in the 1960s after it was traced to thousands of birth
defects
worldwide.","type":"text"}, {"additions":[{"URL":"https://www.nytimes.com/1997/11/28/us/
thalidomide-once-banned-is-in-demand.html?partner=applenews&ad-
keywords=APPLEMOBILE®ion=written through&asset id=100000006090758", "range":{"length"
:61,"start":55},"type":"link"},{"URL":"https://www.nytimes.com/1997/11/28/us/thalidomid
e-once-banned-is-in-demand.html?partner=applenews&ad-
keywords=APPLEMOBILE®ion=written_through&asset_id=100000006090758", "range":{"length"
:11,"start":116},"type":"link"}],"identifier":"anf-body-
21","inlineTextStyles":[{"range":{"length":358,"start":0},"textStyle":"_anf-ts-
1"},{"range":{"length":358,"start":0},"textstyle":"anf-ts-1"}],"layout":"default-
body", "role":"body","text":"Thalidomide had fallen into obscurity until the 1990s, when
new research suggested it could be useful for a variety of diseases. AIDS activists
were smuggling it into the country and selling it through black-market “buyers
clubs†after research suggested the drug could be used for AIDS wasting syndrome and
Kaposi sarcoma, two serious complications of AIDS.","type":"text"},{"identifier":" anf-
body-22","inlineTextStyles":[{"range":{"length":187,"start":0},"textstyle":" anf-ts-
1"},{"range":{"length":187,"start":0},"textStyle":"_anf-ts-1"}],"layout": "default-
body", "role":"body","text":"F.D.A. officials, alarmed that a notorious drug was being
sold illicitly, took the unusual step of seeking out drug companies that might be
willing to bring thalidomide to market
legally.","type":"text"}, {"bannerType":"any","identifier":"anf-banner_advertisement-
4","layout":"ComponentLayout-
4","role": "banner advertisement","type":"banner advertisement"},{"identifier":" anf-
body-23","inlineTextStyles":[{"range":{"length":109,"start":0},"textstyle":"_anf-ts-
1"},{"range":{"length":109,"start":0},"textstyle":"_anf-ts-1"}],"layout": "default-
body", "role":"body","text":"Celgene, then a little-known New Jersey company that had
never sold a drug, ultimately took up the
challenge.","type":"text"}, {"additions":[{"URL":"https://www.hrsa.gov/hansens-
disease/clinical-
center.html","range":{"length":38,"start":113},"type":"link"}],"identifier":"anf-body-
24","inlineTextStyles":[{"range":{"length":251,"start":0},"textstyle":" anf-ts-
1"},{"range":{"length":251,"start":0},"textStyle":"anf-ts-1"}],"layout":"default-
body", "role":"body", "text":"In 1998, Celgene’s application was approved to treat
erythema nodosum leprosum, a complication of leprosy, which is extremely rare in the
United States. In 2007, Celgene said that just 100 prescriptions a year were written to
treat the skin condition.","type":"text"},{"identifier":" anf-body-
25","inlineTextStyles":[{"range":{"length":256,"start":0},"textStyle":" anf-ts-
1"},{"range":{"length":256,"start":0},"textStyle":"_anf-ts-1"}],"layout": "default-
body", "role":"body","text": "But leprosy was hardly the point: The F.D.A.’s main goal
was to keep the drug from harming infants, and it did so by requiring that Celgene set
up a first-of-its-kind distribution system that would limit prescriptions to
preapproved doctors and pharmacies.","type":"text"},{"identifier":"_anf-body-
26","inlineTextStyles":[{"range":{"length":320,"start":0},"textStyle":"_anf-ts-
1"},{"range":{"length":320,"start":0},"textStyle":"_anf-ts-1"}],"layout": "default-
body", "role": "body","text":"Celgene, meanwhile, had ambitious plans. Thalidomide was
generating intense excitement in the medical world, and from the start the company made
clear it would not stop at treating leprosy. Celgene needed a finance executive to
HOUSE_OVERSIGHT_028417
body", "role":"body","text":"Any broad swing in voter opinion could prove difficult for
Mr. Hugin to overcome. Even with Mr. Menendez’s vulnerabilities, New Jersey has
nearly 900,000 more registered Democrats than Republicans, and a number of competitive
House races that have attracted national
attention.","type":"text"}, {"bannerType":"any","identifier":"anf-banner_advertisement-
3","layout":"ComponentLayout-
4","role":"banner_advertisement","type":"banner_advertisement"},{"identifier":"anf-
heading4-1","layout":"heading4","role":"heading4","text": "A once-notorious drug becomes
a lucrative cancer weapon", "type":"text"},{"identifier":"
anf-body-
19","inlineTextStyles":[{"range":{"length":235,"start":0},"textStyle":"_anf-ts-
1"},{"range":{"length":235,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-
body", "role":"body","text":"When Mr. Hugin arrived at Celgene in June 1999, the company
was struggling to figure out how to turn a profit on its only marketed drug, Thalomid,
which had been approved a year earlier to treat a rare skin condition caused by
leprosy.","type":"text"},{"identifier":" anf-body-
20","inlineTextStyles":[{"range":{"length":158,"start":0},"textStyle":" anf-ts-
1"},{"range":{"length":158,"start":0},"textstyle":"anf-ts-1"}],"layout":"default-
body", "role":"body","text":"Thalomid was Celgene’s brand name for thalidomide, an old
drug that became notorious in the 1960s after it was traced to thousands of birth
defects
worldwide.","type":"text"}, {"additions":[{"URL":"https://www.nytimes.com/1997/11/28/us/
thalidomide-once-banned-is-in-demand.html?partner=applenews&ad-
keywords=APPLEMOBILE®ion=written through&asset id=100000006090758", "range":{"length"
:61,"start":55},"type":"link"},{"URL":"https://www.nytimes.com/1997/11/28/us/thalidomid
e-once-banned-is-in-demand.html?partner=applenews&ad-
keywords=APPLEMOBILE®ion=written_through&asset_id=100000006090758", "range":{"length"
:11,"start":116},"type":"link"}],"identifier":"anf-body-
21","inlineTextStyles":[{"range":{"length":358,"start":0},"textStyle":"_anf-ts-
1"},{"range":{"length":358,"start":0},"textstyle":"anf-ts-1"}],"layout":"default-
body", "role":"body","text":"Thalidomide had fallen into obscurity until the 1990s, when
new research suggested it could be useful for a variety of diseases. AIDS activists
were smuggling it into the country and selling it through black-market “buyers
clubs†after research suggested the drug could be used for AIDS wasting syndrome and
Kaposi sarcoma, two serious complications of AIDS.","type":"text"},{"identifier":" anf-
body-22","inlineTextStyles":[{"range":{"length":187,"start":0},"textstyle":" anf-ts-
1"},{"range":{"length":187,"start":0},"textStyle":"_anf-ts-1"}],"layout": "default-
body", "role":"body","text":"F.D.A. officials, alarmed that a notorious drug was being
sold illicitly, took the unusual step of seeking out drug companies that might be
willing to bring thalidomide to market
legally.","type":"text"}, {"bannerType":"any","identifier":"anf-banner_advertisement-
4","layout":"ComponentLayout-
4","role": "banner advertisement","type":"banner advertisement"},{"identifier":" anf-
body-23","inlineTextStyles":[{"range":{"length":109,"start":0},"textstyle":"_anf-ts-
1"},{"range":{"length":109,"start":0},"textstyle":"_anf-ts-1"}],"layout": "default-
body", "role":"body","text":"Celgene, then a little-known New Jersey company that had
never sold a drug, ultimately took up the
challenge.","type":"text"}, {"additions":[{"URL":"https://www.hrsa.gov/hansens-
disease/clinical-
center.html","range":{"length":38,"start":113},"type":"link"}],"identifier":"anf-body-
24","inlineTextStyles":[{"range":{"length":251,"start":0},"textstyle":" anf-ts-
1"},{"range":{"length":251,"start":0},"textStyle":"anf-ts-1"}],"layout":"default-
body", "role":"body", "text":"In 1998, Celgene’s application was approved to treat
erythema nodosum leprosum, a complication of leprosy, which is extremely rare in the
United States. In 2007, Celgene said that just 100 prescriptions a year were written to
treat the skin condition.","type":"text"},{"identifier":" anf-body-
25","inlineTextStyles":[{"range":{"length":256,"start":0},"textStyle":" anf-ts-
1"},{"range":{"length":256,"start":0},"textStyle":"_anf-ts-1"}],"layout": "default-
body", "role":"body","text": "But leprosy was hardly the point: The F.D.A.’s main goal
was to keep the drug from harming infants, and it did so by requiring that Celgene set
up a first-of-its-kind distribution system that would limit prescriptions to
preapproved doctors and pharmacies.","type":"text"},{"identifier":"_anf-body-
26","inlineTextStyles":[{"range":{"length":320,"start":0},"textStyle":"_anf-ts-
1"},{"range":{"length":320,"start":0},"textStyle":"_anf-ts-1"}],"layout": "default-
body", "role": "body","text":"Celgene, meanwhile, had ambitious plans. Thalidomide was
generating intense excitement in the medical world, and from the start the company made
clear it would not stop at treating leprosy. Celgene needed a finance executive to
HOUSE_OVERSIGHT_028417
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document